GSK2126458 is a potent, highly selective pyridilsulfonamide inhibitor of class 1 isozymes of PI3K in addition to mammalian target of rapamycin (mTOR).21 Originally developed in the oncology setting, GSK2126458 is currently (at the time of writing) being evaluated in a phase I open-label dose escalation trial in subjects with refractory solid tumours or lymphoma (https://clinicaltrials.gov/ct2/show/NCT00972686). This evidence concerns the gene MTOR and lymphoma.